Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (2)

Search Parameters:
Keywords = recombinant CD99 human IgG fusion protein

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
17 pages, 1882 KB  
Article
Phenotypic Profiling and Activation-Associated Expression of CD99 Ligands on Human Leukocytes
by Myint Myat Thu, Nuchjira Takheaw, Witida Laopajon, Watchara Kasinrerk and Supansa Pata
Biology 2026, 15(1), 86; https://doi.org/10.3390/biology15010086 - 31 Dec 2025
Abstract
The immune system comprises a complex network of cells that continuously change during activation, infection, and the maintenance of balance. Immunophenotyping offers valuable insights into the regulation of immune responses. We systematically characterized the expression profile of CD99 ligands across distinct immune cell [...] Read more.
The immune system comprises a complex network of cells that continuously change during activation, infection, and the maintenance of balance. Immunophenotyping offers valuable insights into the regulation of immune responses. We systematically characterized the expression profile of CD99 ligands across distinct immune cell subsets using both conventional and high-dimensional flow cytometry. CD99 ligands were detected on NK cells and monocytes under both resting and IL-2-activated conditions, with non-classical monocytes and CD56 Dim NK cells exhibiting the highest expression levels. Notably, ligand expression in these subsets was further enhanced following IL-2 activation. In contrast, T lymphocytes (CD3+) displayed low basal levels of CD99 ligand expression, which increased modestly upon activation. Cellular activation was accompanied by an expansion of specific immune phenotypes characterized by elevated CD99 ligand expression alongside the upregulation of activation markers such as CD69 and CD137. Collectively, these findings suggest that the expression of the CD99 ligands may serve as an indicator of immune activation and demonstrate subset-specific regulation, particularly in response to IL-2 stimulation. These findings have revealed the distinct expression patterns of CD99 ligands, emphasizing their crucial role in modulating immune responses. Full article
12 pages, 1716 KB  
Article
Comparison of the Immunogenicity of the LZ901 Vaccine and HZ/su Vaccine in a Mouse Model
by Yaru Quan, Chunxia Liu, Xu Lu, Xi Kong, Shuai Yang, Jian Kong, Wenyan Wan, Kaiqin Wang, Kangwei Xu and Ling Peng
Vaccines 2024, 12(7), 775; https://doi.org/10.3390/vaccines12070775 - 15 Jul 2024
Cited by 3 | Viewed by 2726
Abstract
Herpes zoster (HZ) is an infectious disease caused by the reactivation of varicella zoster virus (VZV), with 68% of cases occurring in adults over 50 years of age. HZ/su (Shingrix®) was approved by the Food and Drug Administration in 2017 for [...] Read more.
Herpes zoster (HZ) is an infectious disease caused by the reactivation of varicella zoster virus (VZV), with 68% of cases occurring in adults over 50 years of age. HZ/su (Shingrix®) was approved by the Food and Drug Administration in 2017 for the prevention of HZ in individuals ≥ 50 years of age and showed very good protection from HZ. However, due to the use of the adjuvant AS01B, adverse reactions caused by Shingrix are a concern. Aluminum hydroxide is the most commonly used adjuvant and is widely used in a variety of vaccines. We developed a recombinant zoster vaccine (code: LZ901) consisting of a tetramer of VZV glycoprotein E (gE) and a human Fc fusion protein expressed in CHO cells, an immune complex-like molecule that can be adsorbed with an aluminum hydroxide adjuvant. We compared the immunogenicity of LZ901 with that of HZ/su in BALB/c mice. The results showed that LZ901 induced levels of gE-specific IgG antibodies comparable to those induced by HZ/su, and the results of FAMA titers further demonstrated their similar neutralizing antibody abilities. Most importantly, LZ901 induced higher levels of cell-mediated immunity (CMI) (which plays a decisive role in the efficacy of zoster vaccines) than HZ/su in BALB/c mice. The numbers of cytokine-producing T cells in LZ901-vaccinated mice were significantly greater than those in v-vaccinated mice, and the proportions of CD4+ and CD8+ T cells producing at least two types of cytokines in LZ901-vaccinated mice were significantly greater than those in HZ/su-vaccinated mice. Full article
Show Figures

Figure 1

Back to TopTop